Tags

Type your tag names separated by a space and hit enter

Hormone receptor status and mitotic activity as risk factors for recurrence and death in female breast carcinoma.
Anticancer Res. 1991 Sep-Oct; 11(5):1701-6.AR

Abstract

The estrogen (ER) and progesterone (PR) receptor status, volume corrected mitotic index (M/V index) and other classical prognostic factors were related to disease outcome in a series of 281 women with breast cancer followed up for over 8 years. The M/V index predicted recurrence only in ER+ or PR+ patients (p = 0.002-0.006). Similarly, the recurrence-free survival was related to M/V index only in ER+ (p = 0.0005) or PR+ (p less than 0.0001) patients. In survival analysis, ER+ (p = 0.0037) and PR+ (p less than 0.0001) patients were accurately divided into different prognostic groups by the M/V index, whereas in ER- and in PR-tumours the M/V index had only suggestive predictive value (p = 0.06-0.5). In N-tumours the M/V index predicted recurrence-free survival only in ER+ (p = 0.0228) and in PR+ (p = 0.0087) tumours. In survival analysis of N-tumours, the M/V index predicted cancer-related survival in ER+ (p = 0.0102) and in PR+ (p = 0.0014) tumours. In ER-/PR-, N-tumours, none of the variables tested had any prognostic value. The present results suggest that adjuvant hormone treatment might be indicated in ER+ or PR+ tumours with a M/V index greater than 10, regardless of the axillary lymph node status. The prognosis of ER+ or PR+ tumours with a M/V index less than 10 is favourable, the risk of recurrence being of the order of 15% only during the 10-year follow-up. Thus, the expensive and distressing adjuvant treatments could be omitted for these women with an inherently favourable disease outcome.

Authors+Show Affiliations

Department of Surgery, Kuopio University Hospital, Finland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

1768039

Citation

Aaltomaa, S, et al. "Hormone Receptor Status and Mitotic Activity as Risk Factors for Recurrence and Death in Female Breast Carcinoma." Anticancer Research, vol. 11, no. 5, 1991, pp. 1701-6.
Aaltomaa S, Lipponen P, Eskelinen M, et al. Hormone receptor status and mitotic activity as risk factors for recurrence and death in female breast carcinoma. Anticancer Res. 1991;11(5):1701-6.
Aaltomaa, S., Lipponen, P., Eskelinen, M., Kosma, V. M., Marin, S., Alhava, E., & Syrjänen, K. (1991). Hormone receptor status and mitotic activity as risk factors for recurrence and death in female breast carcinoma. Anticancer Research, 11(5), 1701-6.
Aaltomaa S, et al. Hormone Receptor Status and Mitotic Activity as Risk Factors for Recurrence and Death in Female Breast Carcinoma. Anticancer Res. 1991 Sep-Oct;11(5):1701-6. PubMed PMID: 1768039.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hormone receptor status and mitotic activity as risk factors for recurrence and death in female breast carcinoma. AU - Aaltomaa,S, AU - Lipponen,P, AU - Eskelinen,M, AU - Kosma,V M, AU - Marin,S, AU - Alhava,E, AU - Syrjänen,K, PY - 1991/9/1/pubmed PY - 1991/9/1/medline PY - 1991/9/1/entrez SP - 1701 EP - 6 JF - Anticancer research JO - Anticancer Res VL - 11 IS - 5 N2 - The estrogen (ER) and progesterone (PR) receptor status, volume corrected mitotic index (M/V index) and other classical prognostic factors were related to disease outcome in a series of 281 women with breast cancer followed up for over 8 years. The M/V index predicted recurrence only in ER+ or PR+ patients (p = 0.002-0.006). Similarly, the recurrence-free survival was related to M/V index only in ER+ (p = 0.0005) or PR+ (p less than 0.0001) patients. In survival analysis, ER+ (p = 0.0037) and PR+ (p less than 0.0001) patients were accurately divided into different prognostic groups by the M/V index, whereas in ER- and in PR-tumours the M/V index had only suggestive predictive value (p = 0.06-0.5). In N-tumours the M/V index predicted recurrence-free survival only in ER+ (p = 0.0228) and in PR+ (p = 0.0087) tumours. In survival analysis of N-tumours, the M/V index predicted cancer-related survival in ER+ (p = 0.0102) and in PR+ (p = 0.0014) tumours. In ER-/PR-, N-tumours, none of the variables tested had any prognostic value. The present results suggest that adjuvant hormone treatment might be indicated in ER+ or PR+ tumours with a M/V index greater than 10, regardless of the axillary lymph node status. The prognosis of ER+ or PR+ tumours with a M/V index less than 10 is favourable, the risk of recurrence being of the order of 15% only during the 10-year follow-up. Thus, the expensive and distressing adjuvant treatments could be omitted for these women with an inherently favourable disease outcome. SN - 0250-7005 UR - https://www.unboundmedicine.com/medline/citation/1768039/Hormone_receptor_status_and_mitotic_activity_as_risk_factors_for_recurrence_and_death_in_female_breast_carcinoma_ L2 - https://medlineplus.gov/breastcancer.html DB - PRIME DP - Unbound Medicine ER -